Market cap
$491 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-93 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.6
-
Face value
--
-
Shares outstanding
36,946,200
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Akouos Inc (AKUS)
| 56.4 | -0.2 | 326.0 | 62.7 | -- | -- | -- |
|
BSE Sensex*
| -9.3 | 2.0 | 0.1 | -5.7 | 6.6 | 8.0 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
|---|---|
|
Akouos Inc (AKUS)
| -57.1 |
|
S&P Small-Cap 600
| 25.3 |
|
BSE Sensex
| 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Akouos Inc (AKUS)
|
13.3 | 491.0 | 0.0 | -92.6 | -- | -47.5 | -- | 2.7 |
| 0.4 | 26.6 | 0.3 | -70.2 | -21,080.9 | -217.2 | -- | 1.5 |
Shareholding Pattern
View DetailsAbout Akouos Inc (AKUS)
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral... vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts. Read more
-
Co- Founder, Pres, CEO & Director
Dr. Emmanuel Simons M.B.A., Ph.D.
-
Co- Founder, Pres, CEO & Director
Dr. Emmanuel Simons M.B.A., Ph.D.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Akouos Inc (AKUS)
What is the current share price of Akouos Inc (AKUS) Today?
The share price of Akouos Inc (AKUS) is $13.29 (NASDAQ) as of 09-Dec-2022 09:30 EDT. Akouos Inc (AKUS) has given a return of 62.67% in the last 1 years.
What is the current PB & PE ratio of Akouos Inc (AKUS)?
Since, TTM earnings of Akouos Inc (AKUS) is negative, P/E ratio is not available.
The P/B ratio of Akouos Inc (AKUS) is 2.72 times as on 09-Dec-2022, a 45 discount to its peers’ median range of 4.96 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-3.33
|
1.24
|
|
2020
|
-7.34
|
1.15
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2021
|
-3.33
|
1.24
|
What is the 52 Week High and Low of Akouos Inc (AKUS)?
The 52-week high and low of Akouos Inc (AKUS) are Rs -- and Rs -- as of 21-Jun-2026.
What is the market cap of Akouos Inc (AKUS)?
Akouos Inc (AKUS) has a market capitalisation of $ 491 Mln as on 09-Dec-2022. As per SEBI classification, it is a Small Cap company.
Should I invest in Akouos Inc (AKUS)?
Before investing in Akouos Inc (AKUS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.